• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical

expresspharmaJune 11, 2020

Tag: Marksans Pharma , Metformin extended release tablets , NDMA , Diabetes

Marksans Pharma said it is recalling 11,279 bottles of diabetes drug Metformin extended release tablets due to presence of a cancer causing contaminant.

The company has issued voluntary recall of one batch of Metformin extended release tablets (USP 500 mg) due to detection of NDMA (N-nitrosodimethylamine), Marksans Pharma said in a regulatory filing.

The recalled batch contains 11,279 bottles, it added. Metformin extended release tablets are indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.


Previous:Government lifts export restrictions on HCQ APIs, formulations

Next:Dr Reddy’s Laboratories completes acquisition of Wockhardt’s select business divisions

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

XPS handmade sandwich panels

XPS handmade sandwich panels
rockwool handmade sandwich panel

rockwool handmade sandwich panel
6-chloro-3-methyluracil (agliptin and trogliptin for diabetes)

6-chloro-3-methyluracil (agliptin and trogliptin for diabetes)
Acarbose EP used for Diabetes treatment made in China

Acarbose EP used for Diabetes treatment made in China
Glass magnesium rock wool handmade plate

Glass magnesium rock wool handmade plate
Portable Diabetes Insulin Pen in Attractive Design

Portable Diabetes Insulin Pen in Attractive Design
Moxibustion plaster blank stickers Non-woven composite plaster cloth blank stickers Handmade black p

Moxibustion plaster blank stickers Non-woven composite plaster cloth blank stickers Handmade black p
N-BOC-3-hydroxypiperidine (Lilaliptin for diabetes)

N-BOC-3-hydroxypiperidine (Lilaliptin for diabetes)
Aluminum honeycomb handmade sandwich panel

Aluminum honeycomb handmade sandwich panel
rockwool handmade clean room panels

rockwool handmade clean room panels

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service